Drug Profile
Research programme: diabetic complications therapeutics - Cengent Therapeutics/Dynamis Therapeutics
Latest Information Update: 31 Aug 2007
Price :
$50
*
At a glance
- Originator Cengent Therapeutics; Dynamis Therapeutics
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic complications
Most Recent Events
- 31 Aug 2007 No development reported for Diabetic complications in USA (unspecified route)
- 19 Aug 2005 This programme is still in active development (BIO-2005)
- 18 Nov 2004 Early research in Diabetic complications in USA (unspecified route)